Tag

Incyte

1 article

Incyte Lymphoma Trial Cuts Risk 25%

Incyte's frontMIND Phase 3 trial of tafasitamab + lenalidomide + R‑CHOP in untreated high‑risk DLBCL showed a 25% reduction in progression‑or‑death risk (HR 0.75, p 0.0194). Two‑year progression‑free